Staphylococcus aureus bacteremia is a life-threatening condition associated with a substantial financial burden on the health care system. The use of the GeneXpert^® methicillin-resistant S. aureus (MRSA)/S. aureus blood culture (BC) test for the identification of S. aureus may influence antibiotic stewardship and clinical outcomes. This study assessed the clinical and financial impact of utilizing GeneXpert MRSA/SA in combination with criterion-based testing. The outcomes between October 1, 2018, and June 30, 2019, were evaluated in 65 adult patients who had positive BCs with Gram-positive cocci in clusters. GeneXpert MRSA/SA significantly shortened the time to optimal antimicrobial therapy by 1.7 days (2.5 vs. 44 hr, p < 0.0001). The cost saved because of interventions based on GeneXpert testing results was $4,121. GeneXpert testing has shortened the time to optimal therapy and positively impacted cost, although it had no significant effect on length of hospital stay and mortality rate.

中文翻译：

---

使用 GeneXpert 耐甲氧西林金黄色葡萄球菌/金黄色葡萄球菌血培养检测结合抗生素管理快速鉴定血培养阳性葡萄球菌的影响

金黄色葡萄球菌菌血症是一种危及生命的疾病，给医疗保健系统带来巨大的经济负担。使用 GeneXpert ^®耐甲氧西林金黄色葡萄球菌(MRSA)/金黄色葡萄球菌血培养 (BC) 测试来鉴定金黄色葡萄球菌可能会影响抗生素管理和临床结果。本研究评估了将 GeneXpert MRSA/SA 与基于标准的测试结合使用的临床和财务影响。2018 年 10 月 1 日至 2019 年 6 月 30 日期间的结果在 65 名具有成群革兰氏阳性球菌阳性 BC 的成年患者中进行了评估。GeneXpert MRSA/SA 将达到最佳抗菌治疗的时间显着缩短了 1.7 天（2.5 与 44 小时，p  < 0.0001)。由于基于 GeneXpert 测试结果的干预而节省的成本为 4,121 美元。GeneXpert 测试缩短了获得最佳治疗的时间并对成本产生了积极影响，尽管它对住院时间和死亡率没有显着影响。